The Lancet Haematology/X
Jun 13, 2025, 23:21
Paul J Bröckelmann Shares The Lancet Haematology Commission Update on Adverse Events at EHA 2025
The Lancet Haematology shared a post on X:
“Today at EHA2025 Dr Paul J Bröckelmann shared insights from The Lancet Haematology Commission on Adverse Events.
Our 2025 Series updates priority areas on measuring and managing toxicities in new haematology treatment.”
Paul J Bröckelmann presented updates from The Lancet Haematology Commission’s 2025 Series at EHA 2025, focusing on improving how adverse events are measured and managed in modern haematology therapies.
You Can Find More Posts on Hemostasis Today.
-
Jan 15, 2026, 15:09Louise St Germain Bannon: ISTH Education is Off to An Exciting Start in 2026
-
Jan 15, 2026, 13:12Michele Romoli: What is The Optimal Treatment Strategy After Stroke While on DOAC?
-
Jan 15, 2026, 12:18Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE
-
Jan 15, 2026, 04:52Lucien Blondel on Resolve Stroke: To Be Used In the SCULPT Trial
-
Jan 15, 2026, 04:40Mitchell Elkind: Mental Disorders, Brain Health, and Acute Coronary Syndrome
-
Jan 15, 2026, 04:31Laura Dormer on Comparing Stroke Care in Medicare Advantage Versus Fee-for-Service
-
Jan 14, 2026, 21:15Cihan Ay Congratulates Cornelia Englisch on Successful Completion of Her PHD
-
Jan 14, 2026, 20:53Ana Sachetto on Reporting Negative Results
-
Jan 14, 2026, 16:22Leo Nicolai and Rainer Kaiser Link Procoagulant Platelets and Thromboinflammation in CVD